2011 was a busy year and biosimilars was the hot topic of the year for GaBI Online.
Top 10 most read GaBI Online articles in 2011
Home/Pharma News | Posted 30/03/2012 0 Post your comment
To ensure that none of GaBI Online’s readers have missed out on what happened in 2011, below is a list of the top 10 most read articles in 2011. Follow the links in the titles of each article to remind you what happened over the last year.
*arranged in top 10 order with the most read article listed first
This shows that guidelines are the issues of most interest, followed by a general interest in news and current status around biosimilars development, for instance, opportunities, challenges and approval status around the globe (Brazil, China, Europe). Needless to say, scientific research data is one of the most popular articles within GaBI Online.
If you are interested in contributing a research article in a similar area to GaBI Journal, please send us your submission here.
GaBI’s mission – building trust in cost-effective treatments
Editor’s comment
What do you think about GaBI Online providing overviews of this type? Please feel free to share your thoughts via email or in the comments section below. What other overviews would you like to see?
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
EMS proposes merger with Hypera to form Brazil's largest drugmaker
Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206
Advances for Biocon Biologics’ Stelara and Eylea biosimilars
Comments (0)
Post your comment